Company Overview and News

 
Alimentation Couche-Tard taking a more laid-back approach to selling pot

17h thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
ANCUF ATD.A ANCTF ATD.B

 
Couche-Tard optimistic about PC Optimum loyalty program despite sales drop

2018-09-06 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
ANCUF ATD.A ANCTF ATD.B

 
Alimentation Couche-Tard Inc. (ANCUF) CEO Brian Hannasch on Q1 2019 Results - Earnings Call Transcript

2018-09-06 seekingalpha
Alimentation Couche-Tard Inc. (OTCPK:ANCUF) Q1 2019 Results Earnings Conference Call September 6, 2018 8:00 AM ET
ANCUF ATD.A ANCTF ATD.B

3
CANADA STOCKS-TSX rises on NAFTA deal optimism

2018-09-06 reuters
Sept 6 (Reuters) - Canada’s main stock index rose on Thursday on optimism of a revised North American Free Trade Agreement as top U.S. and Canadian trade negotiators were set for a second day of talks.
ACB ANCUF ATD.A ANCTF ATD.B WEED ACBFF CGOOF CNL CGC MAXR

 
Alimentation Couche-Tard's quarterly profit jumps nearly 25 pct

2018-09-05 reuters
(Reuters) - Alimentation Couche-Tard Inc (ATDb.TO) quarterly profit rose nearly 25 percent on Wednesday as the world’s second-biggest convenience store operator benefited from higher fuel sales.
ANCUF ATD.A ANCTF ATD.B

 
PRESS DIGEST- Canada - Aug 30

2018-08-30 reuters
Aug 30 (Reuters) - The following are the top stories from select Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
ANCUF ATD.A ANCTF ATD.B

 
Alimentation Couche-Tard: A Dividend Growth Investment For The Long Term

2018-08-07 seekingalpha
Alimentation Couche-Tard has grown from one lonely store in Quebec into an international gas station/convenience store giant with over 16,000 locations.
CST ANCUF ATD.A ANCTF ATD.B CST.WI

 
Canadian Dividend All-Stars Expected To Announce Dividend Increases - Week Of Aug 8

2018-08-05 seekingalpha
The month of July only saw one Canadian Dividend All-Star, Alimentation Couche-Tard, announce a dividend increase. Fret not, the summer lull is about to come to an end. It all begins this week where two All-Stars are expected to raised dividends. There are several others overdue for a raise who are also scheduled to report earnings.
RBA TRI SAPIF ANCUF HDIUF ANCTF KEYUF FSZ CIFAF ATD.A ATD.B KEY CIX RBA TRI

10
July Dividend Income Report

2018-08-03 seekingalpha
In September 2017, I received slightly over $100K as a result of the commuted value of my pension plan. I decided to invest 100% of this money into dividend growth stocks. Each month, I publish my dividend income report. I don't do this to brag, I do this to show you it's possible to build a portfolio during an all-time high market. The market will crash… eventually. In the meantime, I'd rather cash some juicy dividends!
VIG FB ANCUF ATD.A HAS ANCTF ATD.B TWTR ITP

25
Logos Capital Q2: Long Industrial Alliance

2018-07-23 seekingalpha
"Do you have the patience to wait till your mud settles and the water is clear? Can you remain unmoving till the right action arises by itself?"
MTYFF LSDAF ANCTF MCK CRTO IPL AC LAS.A HII CERN PWF MTY IPPLF POFNF ANCUF BOFI IAG ITRN BKNG ATD.A ATD.B RHUHF SIS ACDVF JNJ RCH COHR

 
Canadian Dividend All-Stars Expected To Announce Dividend Increases - Week Of July 16

2018-07-15 seekingalpha
It has been the typical mid-summer lull and dividend increases have slowed significantly. There are two Canadian Dividend All-Stars scheduled to report earnings this week, Exchange Income Fund (OTCPK:EIFZF)[TSX:EIF] and Atrium Mortgage Investment Corp. (OTC:AMIVF)[TSX:AI]. Neither are expected to raise dividends as both have already announced a dividend bump earlier this year. That being said, earnings are scheduled to ramp up, so let’s revisit some of the action from the past number of weeks.
ANCUF ATD.A ANCTF ATD.B AI EIF AMIVF EIFZF EMLAF

 
Oakmark International Fund: Second Quarter 2018

2018-07-11 seekingalpha
The Oakmark International Fund declined 5.0% for the quarter ended June 30, 2018, underperforming the MSCI World ex U.S. Index, which declined 0.8% over the same period.
ANCUF ATD.A ANCTF ATD.B EXPGF EXPGY RBGLY DDAIF RB

 
Couche-Tard on lookout for new acquisitions after blockbuster year

2018-07-10 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
CST ANCUF ATD.A ANCTF ATD.B CST.WI

 
Alimentation Couche-Tard Inc. (ANCUF) CEO Brian Hannasch on Q4 2018 Results - Earnings Call Transcript

2018-07-10 seekingalpha
Good morning. My name is Teresa, and I will be your conference operator today. I would now like to introduce you to Ms. Marie-Noelle Cano, Senior Director, Global Communications of Alimentation Couche-Tard.
CST ANCUF ATD.A ANCTF ATD.B CST.WI

1
UPDATE 1-Alimentation Couche-Tard beats estimates on fuel sales, acquisitions

2018-07-09 reuters - 1
(Reuters) - Alimentation Couche-Tard Inc (ATDb.TO) topped analysts’ quarterly profit estimate on Monday as the world’s second-biggest convenience store operator benefited from higher fuel sales and its acquisitions.
ANCUF ATD.A ANCTF ATD.B

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...